• Home
  • About Us
  • Technology
  • Pipeline
  • Team
  • Partnerships
  • Media
  • Publications
  • Contact Us
HDT Bio

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models – Science Translational Medicine

Aug 7, 2024 | Publications-Amplify

Click here to view...

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation

Jul 24, 2023 | Publications-Amplify

Click here to view...

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned – PLOS Pathogens

Apr 19, 2023 | Publications-Amplify

Click here to view...

Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model – Molecular Therapy

Mar 24, 2023 | Publications-Amplify

Click here to view...

Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen — Tuberculosis

Feb 1, 2023 | Publications-Amplify

Click here to view...

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis – Vaccines 2023

Feb 1, 2023 | Publications-Amplify

Click here to view...
« Older Entries

Recent Posts

  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
  • HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
  • HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow